ArticleEuropean journal of nuclear medicine and molecular imaging2025
Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE)
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MARBLE: An in vivo MRI marker of limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers.European journal of clinical investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to test the ability to visually detect the characteristic medial temporal and limbic hypometabolic pattern of limbic age-related TDP-43 encephalopathy (LATE) in 18F-FDG-PET of patients with amnestic mild cognitive impairment (aMCI) and evaluate its prognostic value.
methodsWe included 70 patients with aMCI who underwent 18F-FDG-PET, amyloid-PET, tau-PET, and structural MRI, as well as baseline and follow-up cognitive evaluation. 18F-FDG-PET scans were analyzed visually with single-subject maps, categorized as normal, Alzheimer's disease (AD)-like, LATE-like, or other neurodegenerative diseases, while blinded from other data. Clinical and biomarker features as well as cognitive trajectories were compared between groups.
results25 scans were classified as normal, 25 as AD-like, 12 as LATE-like, and 8 as others. Patients with AD-like patterns were younger, had lower MMSE scores, inferior-to-medial temporal metabolism ratio, and greater hippocampal atrophy and cortical tau load than subjects with normal scans. Patients with LATE-like patterns had lower MMSE scores and more hippocampal atrophy than subjects with normal scans. Patients with LATE-like patterns were significantly older, had greater inferior-to-medial temporal metabolism ratio, greater amygdalar atrophy, and lower cortical tau load than subjects with AD-like patterns. Only subjects classified as AD-like showed a faster cognitive decline than negative scans.
conclusionLATE-like hypometabolic pattern in aMCI can identify a subgroup of subjects distinct from AD and controls in terms of clinical severity, medial temporal atrophy, cortical tau load, and cognitive decline, supporting the utility of 18F-FDG-PET as a biomarker that provides inferential support for the specific detection of LATE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.